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Abstract. Maintaining good cardiac function for as long as possible is a
major concern for healthcare systems worldwide and there is much inter-
est in learning more about the impact of different risk factors on cardiac
health. The aim of this study is to analyze the impact of systolic blood
pressure (SBP) on cardiac function while preserving the interpretability
of the model using known clinical biomarkers in a large cohort of the
UK Biobank population. We propose a novel framework that combines
deep learning based estimation of interpretable clinical biomarkers from
cardiac cine MR data with a variational autoencoder (VAE). The VAE
architecture integrates a regression loss in the latent space, which enables
the progression of cardiac health with SBP to be learnt. Results on 3,600
subjects from the UK Biobank show that the proposed model allows us
to gain important insight into the deterioration of cardiac function with
increasing SBP, identify key interpretable factors involved in this pro-
cess, and lastly exploit the model to understand patterns of positive and
adverse adaptation of cardiac function.
Key words:Cardiac function; variational autoencoder; cardiac risk fac-
tors
1 Introduction
Preventing the development of heart disease in patients with known risk fac-
tors, such as hypertension, represents a major challenge for healthcare systems
worldwide. Although much is known about how these risk factors influence devel-
opment of disease, the recent availability of large scale databases such as the UK
Biobank represents an excellent opportunity to extend this knowledge. Learn-
ing from a large number of highly detailed, multidimensional cardiac magnetic
resonance (CMR) datasets can help further understanding of how risk factors
impact cardiac function, and tailor medical interventions to individual patients.
Traditionally, machine learning techniques have relied on the use of handcrafted
features to effectively perform a specific task without using explicit instructions.
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2In some cases, the accuracy of these models was limited by the model being
restricted to the use of these features. Recently, deep learning (DL) techniques
have demonstrated a significant increase in performance over traditional machine
learning methods. DL allows features to be learned from the data themselves,
without preselection. One drawback of DL approaches is the lack of interpretabil-
ity, as the learned relationships and features are often abstract and opaque to
human users. Especially in medicine, interpretability and accountability are vital
for two main reasons: (a) they can promote clinician trust in the learned models;
and (b) the use of well-established, interpretable biomarkers allows the models
to be used to better understand disease processes, translate the results to other
populations and to interpret the newly learned information in the light of already
existing clinical scientific evidence. For example, complex full 3D cardiac motion
of the heart can be used to outperform current models in survival estimation for
patients with pulmonary hypertension [1]. While methods like this demonstrate
the power of DL, it is difficult for clinicians to understand the features underly-
ing the predictions and to use the model to better understand the disease.
A large number of biomarkers can be calculated from CMR. These are well-
understood by clinicians and provide comprehensive information about under-
lying physiological processes. However, estimating them all is labour-intensive.
In this paper, we employ a fully automated DL-based pipeline for estimating a
wide range of biomarkers of cardiac function from cine CMR data. Our main
contribution is to propose a framework that enables the interpretability of these
automatically computed biomarkers to be combined with the power of learned
features in DL. This framework is based on the use of a variational autoencoder
with a latent space regression loss (R-VAE), in which the input data are the
clinical biomarkers. In addition, we use a dummy variable in the regression to
differentiate between population groups. We use the proposed method to inves-
tigate the impact of systolic blood pressure (SBP: a measure of hypertension)
on cardiac function in the healthy population differentiated by gender.
Related Work: In the clinical literature, many groups have investigated the
relationship between SBP and ventricular structure, function and geometry [2, 3].
However, most studies only investigated the influence of SBP on global parame-
ters or only in the left ventricle. The proposed pipeline enables a more detailed
investigation of the impact of SBP on cardiac function, as we demonstrate in
Section 4. VAEs have previously been used for identification and visualization of
features in medical image-based classification tasks [4–6], but the features were
still learnt from the data and were not well-established clinical biomarkers as in
our work. DL models have also previously been proposed for regression using in-
terpretable features. For example, Xie et al. [7] proposed an autoencoder-based
deep belief regression network to forecast daily particulate matter concentra-
tions. Similarly, Bose et al. [8] proposed a stacked autoencoder based regression
framework to optimize process control and productivity in intelligent manufac-
turing. Both techniques combined handcrafted features obtained from the image
domain with autoencoders. In the medical field, Xie et al. [9] have proposed a
deep autoencoder model for regression of gene expression profiles from genotype.
3Similar to these works we integrate a regression loss into the autoencoder to learn
relationships between the latent space and another variable (SBP in our case).
Our work is methodologically distinct from [7–9] as we employ a VAE, which
enables us to sample from the distribution of the latent space and decode the
clinical biomarkers for these samples. We also employ a dummy variable in the
regression to enable the investigation to be stratified by gender. Our work also
represents the first time that a regression-based autoencoder has been applied
to investigate the impact of risk factors on cardiac function.
2 Materials
We evaluate our approach on subjects selected from the UK Biobank data set,
which contains multiple imaging and non-imaging information from more than
half a million 40-69 year-olds. We included only participants with CMR imaging
data. From this group, we excluded participants with a history of cardiovascu-
lar disease, respiratory disease, renal disease, cancer, rheumatological disease,
symptoms of chest pain or dyspnoea. For each subject, the following cine CMR
acquisitions were used; a short-axis (SA) stack covering the full heart, and two
orthogonal long-axis (LA) acquisitions (2-chamber (2Ch) and 4-chamber (4Ch)
views). For each image slice 50 temporal frames were available covering a full
cardiac cycle (temporal resolution ≈14-24 ms/frame). All CMR imaging was
carried out on a 1.5 Tesla scanner (Siemens Healthcare, Erlangen, Germany).
Details of the image acquisition protocol can be found in [?]. Blood pressure
was measured using the HEM-70151T digital blood pressure monitor (Omron,
Hoofddorp, The Netherlands) [10]
3 Methods
In the following sections we first describe the automated estimation of biomark-
ers of cardiac function from CMR images, and secondly present the R-VAE net-
work used to learn the relationship between cardiac function and SBP. Figure 1
summarizes these steps and how they interrelate.
Fig. 1. Overview of the proposed framework for a VAE regression model based on
automatically estimated clinical biomarkers.
43.1 Biomarker Estimation From CMR
The procedure used to extract the clinical biomarkers of cardiac function is based
on the work published in [11] and is briefly summarized below.
Automatic segmentation network: We first used a fully-convolutional
network with a 17 convolutional layer VGG-like architecture for automatic seg-
mentation of the left ventricle (LV) blood pool, LV myocardium and right ven-
tricle (RV) blood pool from SA and LA slices in all frames through the cardiac
cycle [12, 13]. After this, all segmentations were aligned to correct for breath-hold
induced motion artefacts using the iterative registration algorithm proposed in
[13].
Biomarker calculation: LV and RV blood volume curves were calculated
from the obtained segmentations. From these curves, end-diastolic volume (EDV),
end-systolic volume (ESV), stroke volume (SV), ejection fraction (EF), LVED
mass (LVEDM), peak ejection rate (PER), peak early filling rate (PEFR), atrial
contribution (AC) and peak atrial filling rate (PAFR) were obtained. Cardiac
volumes were indexed to body surface area (BSA) using the Dubois and Dubois
formula [14]. The complete list of biomarkers calculated was: iLVEDV (indexed
LVEDV), iLVSV, LVEDM, LVPER, LVPFR, LVPAFR, LVAC, iRVEDV, RVPER,
RVPFR, RVPAFR and RVAC.
Quality control: Similar to [11], two quality control (QC) methods were
implemented to automatically reject subjects with insufficient image quality or
incorrect segmentations, ensuring the robustness of the estimated biomarkers.
The first QC step (QC1) used trained DL models to reject any image with poor
quality or incorrect planning, and the second QC step (QC2) detected incor-
rect segmentation results using an SVM model that identified physiologically
unrealistic or unusual volume curves.
3.2 Deep Learning Regression Model
To combine the interpretability of handcrafted features with the power of DL we
propose to use a VAE featuring a regression loss in the latent space to simulta-
neously learn efficient representations of cardiac function and map their change
with regard to differences in SBP. As a regression model we used the multivari-
able regression modelling commonly used in epidemiological studies [15], where
the effect of different independent variables are included as confounders on the
regression model. As a result, the VAE linearizes the relationship between differ-
ent clinical biomarkers and the variable of interest (SBP in this case), and these
features are incorporated in a standard regression model.
Variational autoencoder: The encoding part of a VAE allows a number
of features, x, to be mapped into a lower dimensional representation (the latent
space), whilst the decoder maps this representation back to the original higher
dimensional space. The proposed VAE has N = 13 input units representing the
clinical biomarkers, two hidden layers with 8 and 4 hidden units respectively and
a latent space of dimensionality 2. To avoid over-fitting we apply dropout with
probability 0.3 after each hidden layer during training.
5Linear regression with indicator (dummy) variable: We use a linear
regression model in the latent space to estimate SBP, that incorporates a dummy
variable (encoded as 0 or 1) to differentiate between population groups. In our
experiments we used gender as a dummy variable, but the method is general
and could be used to investigate a wide range of other factors. Mathematically,
the linear regression model can be formulated as follows: y = wT (z + D) + ,
where z are the latent space activations, D the dummy variable, y the ground
truth label (i.e. SBP) and w the regression coefficients. The regression loss is the
mean squared error: Lregression =
1
N
N∑
t=1
(yi − wTi (zi +Di))2.
Joint learning for regression: We denote the input data by x = [x1, x2, ...xN ]
(i.e. a vector of N = 13 clinical biomarkers) and its corresponding latent space
representation as z = [z1, z2].The decoded clinical biomarkers are denoted by
xˆ = [xˆ1, xˆ2, ...xˆN ], and the predicted label by yˆ = Regressor(z). We combine the
VAE loss and the regression loss by minimising the following joint loss function:
LR−VAE = Lrecon + αLKL + βLregression (1)
where α and β control the weights of the components of the loss function, LKL
is the Kullback-Leibler divergence between the learnt latent distribution and a
unit Gaussian, and Lregression is the Huber loss for the regression task. We first
train the model only using the VAE loss, i.e. β = 0, and secondly train both the
VAE and the regression together using β = 2. We set α = 0.3 throughout.
4 Experiments and Results
Using our selection criteria, 3,781 subjects were included in our experiments. Of
these, 54 subjects were rejected during QC1, and a further 127 during QC2. The
remaining 3,600 cases were used to build the models. Of these cases, 1,321 had
normotension (SBP <120 mmHg), 1,697 hypertension (SBP >140 mmHg) and
582 cases had prehypertension (a SBP between 120 and 140 mmHg).
Experiment 1 - Comparative evaluation on regression task:
We compared our proposed R-VAE model with two state-of-the-art techniques
for multivariate regression: (1) Lasso regression, a linear regression model with a
l1 regularizer [16]; and (2) Random Forest regression [17], an ensemble method
that has shown excellent performance in complex regression and classification
tasks. For all methods, we used a five-fold cross validation to obtain the optimal
model. We split the dataset into training, validation and test (60/20/20), and
optimized the hyperparameters using a grid search strategy. We calculated the
root-mean-square deviation (RMSD), the normalized root-mean-square devia-
tion (nRMSD), and the coefficient of determination (R2) between the ground
truth SBP and the predicted SBP. Table 1 shows these results. It can be seen
that all methods performed similarly with regard to regression. However, note
that the next two experiments are only made possible by our use of the R-VAE
architecture and would not be possible with the other regression techniques.
6Table 1. Comparison of R-VAE, Lasso regression and Random Forest regression.
Methods RMSD (mmHg) nRMSD (mmHg) R2(%)
Lasso [16] 13.2 0.11 0.35
Random Forest [17] 12.98 0.12 0.33
R-VAE 11.36 0.10 0.69
Experiment 2 - Investigating the effect of SBP on cardiac function:
We applied our R-VAE network to investigate how cardiac function changes with
increasing SBP in healthy individuals, stratified by gender. We applied our R-
VAE network to investigate how cardiac function changes with increasing SBP
in healthy individuals, stratified by gender. We sampled the latent space of the
model along the regression line for different SBP values (between 100 to 170
mmHg in steps of 10 mmHg). At each step, we took 20 random samples from a
normal distribution in a perpendicular direction to the regression line and used
the R-VAE to decode the clinical biomarkers. Figure 2 shows the means and
standard deviations for a selection of the decoded biomarkers stratified by gen-
der. The results show that iLVEDV (indexed LVEDV) decreases with increasing
SBP, while iRVEDV (indexed RVEDV) remains constant. LVPAFR and LVPER
increase with increasing SBP. For both iLVEDV and LVPER, the change seems
to be larger in males compared to females. Overall, the observed changes in the
models’ predictions suggest that parameters associated with diastolic function of
the LV are mostly affected by SBP, while the RV was less affected. These results
suggest that stiffening of the LV myocardium could be an important disease
process in deterioration of cardiac function in the light of increased SBP.
Fig. 2. SBP-related changes in iLVEDV, iRVEDV, LVPAFR and LVPER. Red rep-
resents females and blue represents males. Bars represent standard deviations. Black
dotted lines represent the linear tendency curves between the cardiac biomarkers and
ground-truth SBP data.
Experiment 3 - Identifying abnormal response:
In the normal population, some individuals with prehypertension might be pre-
disposed to increased risk of cardiac disease, while others are not. We used our
R-VAE model to identify subjects from the prehypertension group in whom
predicted SBP was lower (i.e. predicted normotension) or higher (i.e. predicted
hypertension) based on the latent space regression, assuming that being wrongly
7classified as normotensive or hypertensive identifies individuals with low versus
increased risk of developing cardiac disease. Subsequently, we decoded the car-
diac biomarkers for these cases using latent features at the regression line of
their true SBP as well as using latent features at their predicted SBP. We cal-
culated the percentage difference for each biomarker for the cases of under- and
over-prediction respectively and investigated which factors contributed most to
the lower or higher prediction in these subjects. Figure 3 shows the mean dif-
ference of selected biomarkers that lead to classification as normotensive (dark)
and hypertensive (light). Biomarkers related to LV diastolic function (blue bars)
showed the largest changes with regard to the under- and overprediction. These
results show again that diastolic function of the LV was a major contributor to
the model predictions of SBP. Moreover, they suggest that biomarkers related
to LV diastolic function might be effective when trying to stratify cardiac risk,
in particular in subjects with ‘prehypertension’.
Fig. 3. Mean change (percentage) of each biomarker in prehypertension cases that were
classified by the regression model as normotensive (dark) and hypertensive (light) with
respect to values predicted by the model using the actual observed SBP. Values further
away from zero mean a larger impact of these biomarkers.
5 Discussion
In this paper, we have presented an automated DL method for analysing cardiac
function and predicting cardiac risk profiles from CMR. Our framework encom-
passes all steps from CMR segmentation through quality control to modelling of
8the impact of SBP, a known cardiovascular risk factor, on cardiac function.
Instead of inputting CMR images directly into the R-VAE, we chose to first
automatically estimate clinical biomarkers from the images. Combined, these
biomarkers give a comprehensive description of cardiac function and are well-
understood by clinicians. While some of the information of the high dimensional
image data is inevitably lost by this approach, it allows the model to be inter-
pretable by clinicians directly.
The combination of the VAE with the regression loss allowed us to decode the
clinical biomarkers from the latent space, while also providing a mapping of these
biomarkers to another variable, SBP. As we show in Experiment 2, this design
enabled us to get a clear description of the changes in cardiac function that occur
with increasing SBP. Using the trained model, we showed that increases in SBP
are mainly linked to changes in diastolic LV function. This suggests that SBP
results in slowly progressive changes in the myocardium that increase ventricular
stiffening. As shown in Experiment 3, the model also allowed us to identify key
factors separating high and low risk subjects. Again, due to the interpretability
of the framework, this allowed us to identify biomarkers that could be further
investigated for their utility in screening patients in clinical practice. SBP is not
the only factor influencing cardiac function and that explains the relatively low
R2 of the regression models. In this paper, we used SBP as an example to illus-
trate the potential power of our proposed method. We aim to further extend our
model in the following ways: we plan to include image and segmentation data
directly into the model, in combination with the clinical biomarkers to maintain
interpretability; we also plan to extend the model to investigate more risk fac-
tors. In conclusion, this work represents a novel use of DL which has produced
an important contribution to furthering our understanding of the influences on
cardiac function.
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